Capricorn Fund Managers’s Belite Bio BLTE Stock Holding History

Capricorn Fund Managers’s Portfolio BLTE Stock Details BLTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-6,400	Closed	-$986K	–	148
2026 Q2	$986K	Buy	+6,400	New	+$981K	0.08%	142

Other funds holding BLTE

Eventide Asset Management Boston, Massachusetts $7.14B AUM 65.02% 1-Year Est. Return

Neuberger Berman Group New York $148B AUM 31.56% 1-Year Est. Return

Affinity Asset Advisors New York $2.46B AUM 196.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Patient Square Capital Menlo Park, California $627M AUM 115.4% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

NWI Management New York $2.67B AUM 61.94% 1-Year Est. Return

Walleye Capital New York $109B AUM 29.28% 1-Year Est. Return

Capricorn Fund Managers's BLTE Position: Q3 2026 in Review

Capricorn Fund Managers sold out of Belite Bio (BLTE) in Q3 2026, closing a stake of 6,400 shares — an estimated $986K sold.

Capricorn Fund Managers first reported a position in BLTE in Q2 2026 and held it in 1 quarter. The position peaked at $986K in Q2 2026. 51 funds tracked by Wall St. Rank hold BLTE as of Q3 2026.

Capricorn Fund Managers reported no remaining Belite Bio position as of Q3 2026 after selling out during the quarter.
Capricorn Fund Managers sold 6,400 Belite Bio shares in Q3 2026, an estimated $986K.
Capricorn Fund Managers first reported a position in Belite Bio in Q2 2026 and held it in 1 quarter.
Capricorn Fund Managers's Belite Bio position peaked at $986K in Q2 2026.
51 funds tracked by Wall St. Rank held Belite Bio as of Q3 2026.

Based on Capricorn Fund Managers's 13F filing for Q3 2026, filed 3 Nov 2026.